<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00213512</url>
  </required_header>
  <id_info>
    <org_study_id>2002/020/HP</org_study_id>
    <nct_id>NCT00213512</nct_id>
  </id_info>
  <brief_title>Effect of Anti CD20 in Pemphigus Desease</brief_title>
  <official_title>Traitment of Patients Presenting Pemphigus With Anti CD20 (Mabthera).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      to treat in an open non comparative clinical study patients presenting pemphigus with
      corticodependance, corticoresistance and contre-indication to systemic steroids.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>primary end-point was the rate of CR three months after the last infusion of Rituximab</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>secondary end-points were :</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of CR during the study period</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time from the start of Rituximab to CR</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number and length of time to relapses</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment tolerance</measure>
  </secondary_outcome>
  <enrollment>22</enrollment>
  <condition>Pemphigus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mabthera</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age&gt;18

          -  pemphigus corticoresistant

          -  pemphigus cortico dependant

          -  contre-indications : syst√©mic steroids

        Exclusion Criteria:

          -  age &lt; 18

          -  cardiopathie

          -  pregnant woman

          -  absence contraception

          -  no consentment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>pascal Joly, MD-PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UH-Rouen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UH-Rouen</name>
      <address>
        <city>Rouen</city>
        <state>Seine maritime</state>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>June 17, 2013</last_update_submitted>
  <last_update_submitted_qc>June 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemphigus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

